Humacyte, Inc. (HUMA) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 79.90M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $79.90M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $48.54M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $50.50M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $19.49M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $38.03M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $62.85M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $44.94M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $20.57M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $93.56M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $115.50M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $80.45M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $99.99M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $114.60M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $129.57M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $149.77M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $163.73M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $181.03M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $198.22M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $217.50M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $240.45M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $383.40K | (m) | (m) |
| 2021-03-31 | (m) | (m) | $513.06K | (m) | (m) |
| 2020-12-31 | (m) | (m) | $1.09M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $1.32M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |